Is Pulmatrix Stock a Good Investment?

Pulmatrix Investment Advice

PULM

To provide specific investment advice or recommendations on Pulmatrix stock, we recommend investors consider the following general factors when evaluating Pulmatrix. This will help you to make an informed decision on whether to include Pulmatrix in one of your diversified portfolios:

Examine Pulmatrix's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Pulmatrix's leadership team and their track record. Good management can help Pulmatrix navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Pulmatrix's business and its evolving consumer preferences.
Compare Pulmatrix's performance and market position to its competitors. Analyze how Pulmatrix is positioned in terms of product offerings, innovation, and market share.
Check if Pulmatrix pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Pulmatrix's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Pulmatrix stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pulmatrix is a good investment.

Sell

Buy

Strong Sell

We provide trade recommendations to complement the recent expert consensus on Pulmatrix. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Pulmatrix is not overpriced, please check all Pulmatrix fundamentals, including its price to sales, book value per share, working capital, as well as the relationship between the cash and equivalents and number of employees . Given that Pulmatrix has a number of shares shorted of 52.87 K, we recommend you to check out Pulmatrix market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.

Market Performance	Insignificant	Details
Volatility	Moderately volatile	Details
Hype Condition	Over hyped	Details
Current Valuation	Fairly Valued	Details
Odds Of Distress	High	Details
Economic Sensitivity	Moves indifferently to market moves	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Not Available	Details
Financial Strenth (F Score)	Frail	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine Pulmatrix Stock

Researching Pulmatrix's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 2.99. The company recorded a loss per share of 2.64. Pulmatrix last dividend was issued on the 6th of February 2019. The entity had 1:20 split on the 1st of March 2022.

To determine if Pulmatrix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulmatrix's research are outlined below:

	Pulmatrix is way too risky over 90 days horizon
	Pulmatrix appears to be risky and price may revert if volatility continues
	Pulmatrix has high likelihood to experience some financial distress in the next 2 years
	The company reported the previous year's revenue of 7.3 M. Net Loss for the year was (14.12 M) with loss before overhead, payroll, taxes, and interest of (671 K).
	Pulmatrix currently holds about 42.91 M in cash with (15.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
	Pulmatrix has a frail financial position based on the latest SEC disclosures

Pulmatrix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulmatrix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulmatrix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	4th of April 2024 Upcoming Quarterly Report	View
	10th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of April 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Pulmatrix's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.6 M.

Pulmatrix's profitablity analysis

The company has Profit Margin (PM) of (0.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.26.

Determining Pulmatrix's profitability involves analyzing its financial statements and using various financial metrics to determine if Pulmatrix is a good buy. For example, gross profit margin measures Pulmatrix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulmatrix's profitability and make more informed investment decisions.

Basic technical analysis of Pulmatrix Stock

As of the 26th of February, Pulmatrix holds the Semi Deviation of 4.64, coefficient of variation of 1622.22, and Risk Adjusted Performance of 0.0541. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pulmatrix, as well as the relationship between them. Please check Pulmatrix standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Pulmatrix is priced some-what accurately, providing market reflects its current price of 8.28 per share. Given that Pulmatrix has jensen alpha of 0.3806, we recommend you to check out Pulmatrix's recent market performance to make sure the company can sustain itself at a future point.

Pulmatrix's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmatrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Siegert Michelle over three months ago Disposition of 25000 shares by Siegert Michelle of Pulmatrix at 1.06 subject to Rule 16b-3
		Cabell Christopher over three months ago Acquisition by Cabell Christopher of 22100 shares of Pulmatrix at 0.3701 subject to Rule 16b-3
		Gillis Steven over six months ago Acquisition by Gillis Steven of 111 shares of Pulmatrix at 110.0 subject to Rule 16b-3
		Gillis Steven over six months ago Disposition of 880 shares by Gillis Steven of Pulmatrix at 28.0 subject to Rule 16b-3
		Teofilo Raad over a year ago Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3

Pulmatrix's Outstanding Corporate Bonds

Pulmatrix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pulmatrix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pulmatrix bonds can be classified according to their maturity, which is the date when Pulmatrix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	MPLX LP 4125 Corp Bond US55336VAK61	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	PulteGroup 6 percent Corp Bond US745867AT82	View
	PulteGroup 55 percent Corp Bond US745867AW12	View
	PulteGroup 5 percent Corp Bond US745867AX94	View
	PulteGroup 7875 percent Corp Bond US745867AM30	View

View All Pulmatrix Corporate Bonds

Understand Pulmatrix's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Pulmatrix's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.0541
	Market Risk Adjusted Performance	4.47
	Mean Deviation	4.27
	Semi Deviation	4.64
	Downside Deviation	4.91
	Coefficient Of Variation	1622.22
	Standard Deviation	6.34
	Variance	40.24
	Information Ratio	0.0593
	Jensen Alpha	0.3806
	Total Risk Alpha	0.3383
	Sortino Ratio	0.0766
	Treynor Ratio	4.46
	Maximum Drawdown	41.84
	Value At Risk	(9.54)
	Potential Upside	12.77
	Downside Variance	24.13
	Semi Variance	21.54
	Expected Short fall	(5.24)
	Skewness	1.66
	Kurtosis	7.07

	Risk Adjusted Performance	0.0541
	Market Risk Adjusted Performance	4.47
	Mean Deviation	4.27
	Semi Deviation	4.64
	Downside Deviation	4.91
	Coefficient Of Variation	1622.22
	Standard Deviation	6.34
	Variance	40.24
	Information Ratio	0.0593
	Jensen Alpha	0.3806
	Total Risk Alpha	0.3383
	Sortino Ratio	0.0766
	Treynor Ratio	4.46
	Maximum Drawdown	41.84
	Value At Risk	(9.54)
	Potential Upside	12.77
	Downside Variance	24.13
	Semi Variance	21.54
	Expected Short fall	(5.24)
	Skewness	1.66
	Kurtosis	7.07

Consider Pulmatrix's intraday indicators

Pulmatrix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pulmatrix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	1750.38
	Daily Balance Of Power	1.125
	Rate Of Daily Change	1.06
	Day Median Price	8.2
	Day Typical Price	8.23
	Price Action Indicator	0.3
	Period Momentum Indicator	0.45
	Relative Strength Index	58.68

Pulmatrix time-series forecasting models is one of many Pulmatrix's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pulmatrix's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pulmatrix Stock media impact

Far too much social signal, news, headlines, and media speculation about Pulmatrix that are available to investors today. That information is available publicly through Pulmatrix media outlets and privately through word of mouth or via Pulmatrix internal channels. However, regardless of the origin, that massive amount of Pulmatrix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Pulmatrix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulmatrix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulmatrix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulmatrix alpha.

Pulmatrix Corporate Management

MBA CMA	Interim Officer	Profile
Alexander Klibanov	Founder	Profile
Margaret MD	Chief Officer	Profile
David JD	Advisor	Profile
Aidan Curran	VP Affairs	Profile

When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports: